Shares in AstraZeneca ticked up after the Anglo-Swedish drugs giant announced a tie-up with biotechnology giant Amgen to develop and commercialise five treatments.
Under the terms of the agreement, Astra will make a one-off upfront payment of $50m and the companies will share costs and profits on the drugs for a variety of inflammatory, respiratory and auto-immune diseases.
{iframe}http://menmedia.co.uk/manchestereveningnews/news/business/deals/s/1490224_astrazeneca-links-up-with-amgen-for-treatments-development{/iframe}